CORRECTED-Valeant reports fourth-quarter loss on acquisition costs

Thu Feb 28, 2013 6:45am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Corrects paragraph 3 to say product sales, not revenue, rose 45 pct)

Feb 28 (Reuters) - Canadian drug maker Valeant Pharmaceuticals International Inc reported a fourth-quarter loss, largely due to costs related to its $2.6 billion acquisition of Medicis Pharmaceuticals Corp.

The net loss was $89.1 million, or 29 cents per share, compared with a profit of $55.6 million, or 18 cents per share, a year earlier.

Product sales rose 45 percent to $946.7 million.

Interest expenses rose to $160.2 million from $94.1 million. (Reporting by Krithika Krishnamurthy in Bangalore)